<DOC>
	<DOCNO>NCT00135486</DOCNO>
	<brief_summary>The purpose primary vaccination study evaluate immunogenicity , safety reactogenicity three dos GSK Biologicals ' MenC-TT ( Neisseria meningitidis group C polysaccharide-tetanus toxoid ) vaccine ( 2 different formulation ) three dos GSK Biologicals ' Hib-MenC-TT ( Haemophilus influenzae type b-MenC-TT ) vaccine ( 2 different formulation ) give infant 3rd , 4th , 5th month life . Concomitant vaccine give child complete vaccination agenda .</brief_summary>
	<brief_title>Study Evaluate GlaxoSmithKline ( GSK ) Biologicals ' MenC-TT Vaccine Hib-MenC-TT Vaccine Infants</brief_title>
	<detailed_description>Five parallel treatment group receive 3-dose primary vaccination course : MenC-TT vaccine ( 2 formulation , double-blind ) + Infanrix hexa® OR Hib-MenC-TT ( 2 formulation double-blind ) + Infanrix penta® OR Meningitec™ + Infanrix hexa® ( control ) . Three blood sample take , dose 1 one month dose 2 dose 3 .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female infant , 8 16 week age time first vaccination . Previous vaccination OR history OR exposure since birth diphtheria , pertussis , tetanus , polio , hepatitis B , Hib and/or meningococcal disease . Planned administration/administration vaccine foreseen study since birth . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History neurologic disorder seizure , allergic disease reaction likely exacerbate component vaccine</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Haemophilus Influenzae type b/Meningococcal vaccine</keyword>
	<keyword>Prophylaxis meningococcal serogroup C disease , Hib disease</keyword>
</DOC>